OBJECTIVES: To estimate the burden and economic burden of Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Colombian population.

METHODS: Since newborn population to 100 years old, using a Markov model, the healthy years of life of AVISAS (DALYs) and the economic burden by sex and age in Colombian population were estimated. The information was obtaining from literature review, international clinical guidelines, disability global report, patients survey, national data about medications and procedures.

RESULTS: PAH without treatment generates 13,496 potentially lost DALYs, most of them due to premature mortality (13,321). When performing specific treatment of patients with PAH, there is an improvement of 7,665 DALYs (57% improvement), especially due to a decrease in premature mortality by 58%, increasing the years of disability by 5%. In patients with CTEPH without specific treatment, 14,493 DALYs are lost, the majority due to premature death (12,794). When performing the complete specific treatment (thromboendarterectomy and specific medication) there is an improvement of 6,378 DALYs (44%) especially due to a decrease in premature deaths (5,508 DALYs). In patients with APH the economic burden is US $ 65 million without any treatment and when handling is required to invest US $ 251 million more, this leads to a cost for each DALY of the order of US $ 32,862. In the case of CTEPH, the cost without treatment is close to US $ 659 million and when putting surgical and medical treatment you have to make an investment of US $ 826 million, which leads to a reserve of US $ 129,514 for each DALY won.

CONCLUSIONS: Proper management early in both pathologies has an impact on the disease burden and economic impact.